Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dandy

<< Previous

Bullboard Posts

Next >>

Comment by Rawrasauruson Aug 16, 2021 12:17am

165 Views

Post# 33708245

RE:Dandy

Mate, I've watched you posted for ages. We get it. You're short the stock. Just cover, take your 60% gain and get out of here. If you're long, stop the fud. If you took a short position after that drop, you're chasing and are you a bad trader. Either way, move on with your life. This is getting sad.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market